
Naruszenie patentu na drugie zastosowanie medyczne w świetle systemu refundacyjnego
Author(s) -
Marek Świerczyński
Publication year - 2016
Publication title -
internetowy kwartalnik antymonopolowy i regulacyjny
Language(s) - English
Resource type - Journals
eISSN - 2299-5749
pISSN - 2299-8837
DOI - 10.7172/2299-5749.ikar.8.5.1
Subject(s) - scope (computer science) , reimbursement , competition (biology) , business , order (exchange) , law and economics , law , competition law , political science , economics , monopoly , computer science , finance , market economy , ecology , health care , biology , programming language
This paper relates to patent infringements on second medical use in the light of competition law and the reimbursement system. It is inspired by two recent rulings delivered by English and Dutch courts. They have considered whether the sale of generic drugs may be regarded as an infringement of a patent relating to a second medical use (not indicated on the labels) in situations where the facts of the case showed that these drugs have actually been used in a way covered by this patent (i.e. off-label use). In the light of these rulings, the main purpose of this paper is to answer the question whether it is appropriate, in the light of competition law, to limit the scope of the patent on second medical use in situations where drugs based on the substance are subject to reimbursement, in order to provide wider access to these drugs to patients